CTOs on the Move

Phoenix Care Systems

www.phoenixcaresystems.com

 
Phoenix Care Systems, Inc. is the parent company of Willowglen Academy, Inc., Bell Therapy, Inc. and Phoenix Pharmacy, Inc. Willowglen Academy has been a leader in providing community based treatment services to autistic and mentally ill children for nearly 30 years. Bell Therapy, a pioneer in the national movement to de-institutionalize mentally ill adults has been providing innovative treatment services that promote independence, dignity, and diversity, while enhancing the quality of life since 1972.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Health Education Alliance

Health Education Alliance is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

memorial Clinic

memorial Clinic is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Electrical Geodesics

Electrical Geodesics is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OSF Healthcare System

OSF HealthCare is a multi-state healthcare system, providing state-of-the-art, compassionate care to nearly 3 million people in the communities we serve, through 13 acute care facilities and two colleges of nursing. OSF HealthCare is proud to be among the nation`s leading innovators in the transformation of care for better health for our communities, consistently excellent patient experience and lower costs.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.